Detailing Characteristic of Fibrostenotic Crohn’s Disease Biology & the Potential of Locally Activated Pro-Drug PDE4 Inhibitor to Minimize OffTarget Effects & Maximize Therapeutic Efficacy

Time: 2:30 pm
day: Day Two

Details:

  • Discussing the prevalence and clinical presentation of fibrostenotic Crohn’s disease, and the underlying biological mechanisms, focusing on fibrosis pathways and the role of chronic inflammation in disease progression
  • Describing the mechanism of the PDE4 inhibitor and its dual antifibrotic and anti-inflammatory properties
  • The innovative pro-drug approach allowing for local activation in the colon or distal small intestine, aiming to reduce systemic side effects and improve drug specificity

Speakers:

Mitchell Jones